CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Cliff's Journey With CALQUENCE® (acalabrutinib)

This article was sponsored by AstraZeneca.

CALQUENCE® (acalabrutinib) for Patients with Chronic Lymphocytic Leukemia (CLL)

An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center

Jim’s Story with Chronic Lymphocytic Leukemia (CLL)

Treating CLL with CALQUENCE® (acalabrutinib)

Blood Cancer Drug, Copiktra, May Increase Risk of Death, Severe Side Effects, FDA Warns

July 5th 2022, 7:00pm

Article

Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.

Time-Limited Venclexta Regimens Outperform Chemoimmunotherapy in CLL

June 13th 2022, 9:00pm

Article

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022, 10:00pm

Article

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Better Data Needed to Approve Future PI3K Inhibitors for Blood Cancers, FDA Panel Recommends

April 25th 2022, 7:00pm

Article

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

Certain Blood Cancer Treatments Pulled from US Market After Treatment Results Fail to Show Improved Survival

April 21st 2022, 9:00pm

Article

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

FDA Places Partial Hold on Trial Investigating Novel Drug in Patients With Leukemia and Lymphoma

April 12th 2022, 9:00pm

Article

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

Post-Treatment Venclexta Improves Outcomes and Is Well-Tolerated in CLL

April 12th 2022, 1:07pm

Article

Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.

Immunocompromised: Navigating the COVID-19 Pandemic while Living with CLL

March 31st 2022, 12:00pm

Video

Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.

Chronic Lymphocytic Leukemia: Cliff's Journey With CALQUENCE® (acalabrutinib)

March 25th 2022, 1:53pm

Article

This article was sponsored by AstraZeneca.

An ‘Equal Playing Field’ Makes up the Available Treatment Options for CLL

February 27th 2022, 4:00pm

Article

Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.